Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-03 · accession 0000950170-25-003152 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-07 | 2025-01-03 | ANTX | Eizen Joshua M | See Remarks | S - Sale | $1.34 | -9,663 | 116.7K | -8% | -$12.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-03 | S | D | 9,663 | $1.34 | 116,672 | D | — | — | (F1) Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025. (F2) Includes (a) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 (b) 22,500 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025 and (c) 45,000 RSUs which vest as follows: 2/3rd of the RSU vest on January 1, 2026 and 1/3rd of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date. |